Max Planck Institute for Molecular Genetics, Berlin, Germany.
Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin, Berlin, Germany.
Cancer Res. 2020 Dec 15;80(24):5491-5501. doi: 10.1158/0008-5472.CAN-20-1998. Epub 2020 Oct 28.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of all renal cancers and around 30% of chRCC cases have mutations in . chRCC is poorly supported by microvessels and has markably lower glucose uptake than clear cell RCC and papillary RCC. Currently, the metabolic status and mechanisms by which this tumor adapts to nutrient-poor microenvironments remain to be investigated. In this study, we performed proteome and metabolome profiling of chRCC tumors and adjacent kidney tissues and identified major metabolic alterations in chRCC tumors, including the classical Warburg effect, the downregulation of gluconeogenesis and amino acid metabolism, and the upregulation of protein degradation and endocytosis. chRCC cells depended on extracellular macromolecules as an amino acid source by activating endocytosis to sustain cell proliferation and survival. Inhibition of the phospholipase C gamma 2 (PLCG2)/inositol 1,4,5-trisphosphate (IP3)/Ca/protein kinase C (PKC) pathway significantly impaired the activation of endocytosis for amino acid uptakes into chRCC cells. In chRCC, whole-exome sequencing revealed that mutations were not related to expression of PLCG2 and activation of endocytosis. Our study provides novel perspectives on metabolic rewiring in chRCC and identifies the PLCG2/IP3/Ca/PKC axis as a potential therapeutic target in patients with chRCC. SIGNIFICANCE: This study reveals macropinocytosis as an important process utilized by chRCC to gain extracellular nutrients in a p53-independent manner.
嫌色细胞肾细胞癌(chRCC)约占所有肾癌的 5%,约 30%的 chRCC 病例存在. chRCC 的微血管支持较差,葡萄糖摄取量明显低于透明细胞 RCC 和乳头状 RCC。目前,这种肿瘤适应营养贫乏的微环境的代谢状态和机制仍有待研究。在这项研究中,我们对 chRCC 肿瘤和相邻肾组织进行了蛋白质组和代谢组学分析,鉴定出 chRCC 肿瘤中的主要代谢改变,包括经典的沃伯格效应、糖异生和氨基酸代谢下调以及蛋白降解和内吞作用上调。chRCC 细胞通过激活内吞作用依赖细胞外大分子作为氨基酸来源,以维持细胞增殖和存活。抑制磷酯酶 C 伽马 2(PLCG2)/肌醇 1,4,5-三磷酸(IP3)/钙/蛋白激酶 C(PKC)通路显著削弱了 chRCC 细胞内氨基酸摄取的内吞作用激活。在 chRCC 中,全外显子组测序显示 突变与 PLCG2 的表达和内吞作用的激活无关。我们的研究为 chRCC 的代谢重排提供了新的视角,并确定了 PLCG2/IP3/Ca/PKC 轴作为 chRCC 患者潜在的治疗靶点。意义:本研究揭示了巨胞饮作用是 chRCC 以一种不依赖 p53 的方式获得细胞外营养物质的重要过程。